Biotage Logo

Biotage

ISIN: SE0000454746 | Ticker: BIOT | LEI: 529900SR87NBUKX74L58
Sector: Health CareSub-Industry: Health Care Technology
Country: Sweden

About Biotage

Company Description

Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.

Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner – HumanKind Unlimited.

Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs 497 people worldwide. The Group had sales of 1,232 MSEK in 2021 and our products are sold in more than 80 countries. Biotage’s share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm.

Year founded

1999

Served area

Worldwide

Headcount

497

Headquarters

Vimpelgatan 5, 75318 Uppsala – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 1,434,000,000.00 1,992,000,000.00 2,339,000,000.00
Noncurrent Assets N/A 683,000,000.00 1,218,000,000.00 1,308,000,000.00
Property Plant And Equipment N/A 53,000,000.00 76,000,000.00 96,000,000.00
Goodwill N/A 290,000,000.00 741,000,000.00 794,000,000.00
Intangible Assets Other Than Goodwill N/A 129,000,000.00 185,000,000.00 172,000,000.00
Deferred Tax Assets N/A 26,000,000.00 22,000,000.00 23,000,000.00
Other Noncurrent Financial Assets N/A 12,000,000.00 14,000,000.00 21,000,000.00
Current Assets N/A 752,000,000.00 774,000,000.00 1,031,000,000.00
Inventories N/A 160,000,000.00 237,000,000.00 305,000,000.00
Trade And Other Current Receivables N/A 194,000,000.00 180,000,000.00 223,000,000.00
Other Current Nonfinancial Assets N/A 26,000,000.00 46,000,000.00 62,000,000.00
Cash and cash equivalents 186,000,000.00 371,000,000.00 311,000,000.00 441,000,000.00
Equity And Liabilities N/A N/A 1,992,000,000.00 2,339,000,000.00
Equity 876,000,000.00 990,000,000.00 1,371,000,000.00 1,637,000,000.00
Issued Capital N/A 91,000,000.00 92,000,000.00 93,000,000.00
Retained Earnings N/A 956,000,000.00 1,063,000,000.00 1,229,000,000.00
Liabilities N/A 1,434,000,000.00 1,992,000,000.00 N/A
Noncurrent Liabilities N/A 227,000,000.00 307,000,000.00 285,000,000.00
Other Longterm Provisions N/A 3,000,000.00 10,000,000.00 5,000,000.00
Deferred Tax Liabilities N/A 33,000,000.00 73,000,000.00 71,000,000.00
Other Noncurrent Financial Liabilities N/A 51,000,000.00 45,000,000.00 17,000,000.00
Longterm Borrowings N/A 110,000,000.00 150,000,000.00 150,000,000.00
Current Liabilities N/A 217,000,000.00 313,000,000.00 417,000,000.00
Other Shortterm Provisions N/A 8,000,000.00 3,000,000.00 3,000,000.00
Trade And Other Current Payables N/A 51,000,000.00 56,000,000.00 57,000,000.00
Other Current Financial Liabilities N/A 2,000,000.00 2,000,000.00 8,000,000.00
Other Current Nonfinancial Liabilities N/A 135,000,000.00 229,000,000.00 325,000,000.00
Line item in (sek) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 1,092,000,000.00 1,232,000,000.00 1,566,000,000.00
Other Income 21,000,000.00 17,000,000.00 37,000,000.00
Profit Loss From Operating Activities 206,000,000.00 271,000,000.00 327,000,000.00
Finance Income 26,000,000.00 10,000,000.00 35,000,000.00
Finance Costs 9,000,000.00 12,000,000.00 14,000,000.00
Profit Loss Before Tax 223,000,000.00 269,000,000.00 348,000,000.00
Income Tax Expense Continuing Operations 47,000,000.00 64,000,000.00 80,000,000.00
Profit (loss) 175,000,000.00 205,000,000.00 268,000,000.00
Profit Loss Attributable To Owners Of Parent 175,000,000.00 205,000,000.00 268,000,000.00
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A 175,000,000.00 205,000,000.00 268,000,000.00
Adjustments For Reconcile Profit Loss N/A 63,000,000.00 -78,000,000.00 -84,000,000.00
Adjustments For Decrease Increase In Inventories N/A -5,000,000.00 -54,000,000.00 -45,000,000.00
Adjustments For Unrealised Foreign Exchange Losses Gains N/A 6,000,000.00 4,000,000.00 4,000,000.00
Adjustments For Fair Value Gains Losses N/A -25,000,000.00 -9,000,000.00 -28,000,000.00
Other Adjustments For Noncash Items N/A 8,000,000.00 9,000,000.00 7,000,000.00
Adjustments For Reconcile Profit Loss N/A 63,000,000.00 -78,000,000.00 -84,000,000.00
Interest Paid Classified As Operating Activities N/A 3,000,000.00 3,000,000.00 5,000,000.00
Interest Received Classified As Operating Activities N/A 0.00 0.00 2,000,000.00
Cash Flows From Used In Operating Activities N/A 279,000,000.00 353,000,000.00 341,000,000.00
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A 0.00 282,000,000.00 12,000,000.00
Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities N/A 1,000,000.00 2,000,000.00 2,000,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 18,000,000.00 23,000,000.00 35,000,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 43,000,000.00 33,000,000.00 35,000,000.00
Proceeds From Other Longterm Assets Classified As Investing Activities N/A 0.00 0.00 0.00
Cash Flows From Used In Investing Activities N/A -62,000,000.00 -341,000,000.00 -84,000,000.00
Proceeds From Borrowings Classified As Financing Activities N/A 0.00 150,000,000.00 150,000,000.00
Repayments Of Borrowings Classified As Financing Activities N/A N/A 134,000,000.00 180,000,000.00
Cash Flows From Used In Financing Activities N/A -23,000,000.00 -82,000,000.00 -133,000,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A 195,000,000.00 -69,000,000.00 124,000,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -10,000,000.00 9,000,000.00 7,000,000.00
Cash and cash equivalents 186,000,000.00 371,000,000.00 311,000,000.00 441,000,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
05.12.23 Gustaf Peter Reinhold von Ehrenheim Other Other SEK 1,968,000.00
18.07.23 Scott Carr Other Other SEK 0.00
28.04.23 Gustaf Peter Reinhold von Ehrenheim Other Buy SEK 2,015,520.00
20.05.21 Anders Wikström Other Sell SEK 265,500.00
09.11.20 Jon-Sverre Schanche Other Buy SEK 145,000.00
05.10.20 Thomas Eklund Other Sell SEK 2,608,500.00
03.09.20 torben jörgensen Other Sell SEK 76,590.00
06.08.20 Lars Ivar Bäckman Other Sell SEK 1,662,038.00
22.05.20 Esbjörn Jonas Love Amcoff Other Sell SEK 361,260.00
11.05.20 Karolina Lawitz Other Sell SEK 317,500.00

Capital markets information

ISIN

SE0000454746

LEI

529900SR87NBUKX74L58

Sector

Health Care

Industry Group

Health Care Equipment & Services

Industry

Health Care Technology

Sub-Industry

Health Care Technology

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.